Skip to main content

Avastin FDA Approval History

Last updated by Judith Stewart, BPharm on May 5, 2021.

FDA Approved: Yes (First approved February 26, 2004)
Brand name: Avastin
Generic name: bevacizumab
Dosage form: Injection
Company: Genentech, Inc.
Treatment for: Colorectal Cancer, Non-Small Cell Lung Cancer, Glioblastoma Multiforme, Renal Cell Carcinoma, Cervical Cancer, Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Hepatocellular Carcinoma

Avastin (bevacizumab) is a recombinant humanized monoclonal IgG1 antibody for the treatment of colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical cancer, ovarian cancer, fallopian tube cancer, peritoneal cancer, and hepatocellular carcinoma.

Development Timeline for Avastin

DateArticle
Oct 13, 2021Approval  FDA Approves Merck’s Keytruda (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, as Treatment for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS ≥1)
May 29, 2020Approval  FDA Approves Genentech’s Tecentriq in Combination With Avastin for People With Hepatocellular Carcinoma
Dec  6, 2018Approval  FDA Approves Genentech’s Tecentriq in Combination With Avastin and Chemotherapy for the Initial Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
Jun 13, 2018Approval  FDA Approves Genentech’s Avastin (bevacizumab) Plus Chemotherapy as a Treatment for Women With Advanced Ovarian Cancer Following Initial Surgery
Dec  5, 2017Approval  FDA Grants Genentech’s Avastin Full Approval for Most Aggressive Form of Brain Cancer
Dec  6, 2016Approval  FDA Approves Avastin (bevacizumab) Plus Chemotherapy for a Specific Type of Advanced Ovarian Cancer
Nov 14, 2014Approval  FDA Approves Avastin (bevacizumab) Plus Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer
Aug 14, 2014Approval  FDA Approves Avastin for Metastatic Cervical Cancer
Nov 18, 2011Approval  FDA Revokes Breast Cancer Indication for Avastin (bevacizumab)
Aug  3, 2009Approval  FDA Approves Avastin for the Most Common Type of Kidney Cancer
May  6, 2009Approval  FDA Grants Accelerated Approval of Avastin for Brain Cancer (Glioblastoma) That Has Progressed Following Prior Therapy
Feb 25, 2008Approval  FDA Grants Accelerated Approval of Avastin in Combination With Paclitaxel Chemotherapy for First-Line Treatment of Advanced HER2-Negative Breast Cancer
Oct 11, 2006Approval  FDA Approves Avastin in Combination With Chemotherapy for First-Line Treatment of Most Common Type of Lung Cancer
Apr 12, 2006Avastin Filed in US for Treatment of Most Common Form of Lung Cancer
Feb 26, 2004Approval  Avastin Approved for treatment for Metastatic Colorectal Cancer

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.